Corey McCann
-
Devices & Diagnostics, BioPharma
Pear Therapeutics Files for Bankruptcy and Plans for Asset Auction in May
Pear Therapeutics’ Chapter 11 bankruptcy filing follows three corporate restructurings and the inability to secure additional financing to support commercialization of its FDA-cleared prescription digital therapeutics. An auction of Pear’s assets is expected to happen in early May.
-
Pear Therapeutics’ Cuts Are Not Enough; ‘Strategic Alternatives’ Among Next Steps
Pear Therapeutics isn’t meeting the commercialization goals for its prescription digital therapeutics, so it’s now seeking strategic alternatives for the business. Prospective buyers can pick up Pear’s FDA-cleared products for substance use disorder, opioid use disorder, and insomnia.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Opioid addiction app from Novartis and Pear Therapuetics gets FDA nod
The reSET-O prescription mobile application is directed at supporting patients using buprenorphine as a medicinal aid in treatment to overcome opioid addiction.